摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

富马酸溴长春胺 | 84964-12-5

中文名称
富马酸溴长春胺
中文别名
溴长春胺延胡索酸盐;溴长春胺富马酸盐
英文名称
Brovincamine fumarate
英文别名
(E)-but-2-enedioic acid;methyl (15S,17S,19S)-4-bromo-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18)-tetraene-17-carboxylate
富马酸溴长春胺化学式
CAS
84964-12-5
化学式
C4H4O4*C21H25BrN2O3
mdl
——
分子量
549.418
InChiKey
CKCVTPQYFOMHFD-HPJCWFBOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    144°
  • 比旋光度:
    D20 +4.7° (0.388% in H2O)

计算性质

  • 辛醇/水分配系数(LogP):
    3.43
  • 重原子数:
    35
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    129
  • 氢给体数:
    3
  • 氢受体数:
    8

文献信息

  • [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024048A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中POL是聚合物基团,每个Hyp是独立的超支化基团,每个基团SP是独立的间隔基团,每个L是独立的可逆前药连接基团,m为0或1,每个n是独立的整数,范围从2到200,每个x是独立的0或1。此外,还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。
  • [EN] HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS HYDROSOLUBLES DE FORTE CHARGE
    申请人:ASCENDIS PHARMA AS
    公开号:WO2013024047A1
    公开(公告)日:2013-02-21
    The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independendly a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use asmedicament or diagnostic, and methods of treatment.
    本发明涉及水溶性载体连接的前药,其化学式为(I),其中B、A和Hyp形成载体,B是一个分支核心,每个A独立地是一条聚乙二醇基聚合链,每个Hyp独立地是一个分支基团,每个SP独立地是一个间隔基团,每个L独立地是一个可逆前药连接基团,每个D独立地是一个生物活性基团,每个x独立地为0或1,每个m独立地是从2到64的整数,n是从3到32的整数;或其药学上可接受的盐。进一步涉及包括所述水溶性载体连接的前药的药物组合物,其用作药物或诊断,以及治疗方法。
  • [EN] RELEASABLE CONJUGATES<br/>[FR] CONJUGUÉS LIBÉRABLES
    申请人:QUIAPEG PHARMACEUTICALS AB
    公开号:WO2018163131A1
    公开(公告)日:2018-09-13
    The present application provides compounds of Formula (B), or pharmaceutically acceptable salts thereof, wherein D is a residue of a biologically active drug, which underdo hydrolysis under physiological conditions to release the biologically active drug and which are useful in the treatment of disorders that could be beneficially treated with the drug.
    本申请提供了化合物的公式(B),或其药用盐,其中D是生物活性药物的残留物,在生理条件下经过水解释放出生物活性药物,并且对可能受益于该药物治疗的疾病具有用处。
  • CRYSTALLINE CONDITION DISLOCATING METHOD
    申请人:NIPPON SHINYAKU COMPANY, LIMITED
    公开号:EP0665009A1
    公开(公告)日:1995-08-02
    An object of this invention is to provide a method of dislocating the crystalline condition of crystalline medicine simply, speedily and homogeneously, and, moreover, in large quantities at once. This invention is directed to a method using an extruder when crystalline medicine in a certain crystalline condition (△ is dislocated to another crystalline condition (○), i.e., when the dislocation of crystalline condition (△->○) is carried out.
    本发明的目的是提供一种简单、快速和均匀地将结晶药物的结晶状态变位的方法,而且是一次性大量变位。本发明针对的是一种使用挤压机将某种结晶状态(△)的结晶药物变位到另一种结晶状态(○)的方法,即结晶状态(△->○)变位的方法。
  • Adhesive base material
    申请人:KOWA CO. LTD.
    公开号:EP0735122A2
    公开(公告)日:1996-10-02
    An adhesive base material comprises a polymer obtained by polymerizing a glucosyloxy alkyl (meth)acrylate, a hydroxyalkyl (meth)acrylate, an alkyl (meth)acrylate and a polyfunctional monomer. This adhesive base material can be caused to swell uniformly because of its good swelling property and exhibits excellent adhesion to the skin so that it is useful as adhesive layers in plasters, various medical pads and also medicament-impregnated dermatologic medicines.
    一种粘合剂基底材料由一种聚合物组成,该聚合物通过聚合葡糖基氧基烷基(甲 基)丙烯酸酯、羟基烷基(甲基)丙烯酸酯、烷基(甲基)丙烯酸酯和多官能团单体而得。这种粘合剂基底材料具有良好的膨胀性,可使皮肤均匀膨胀,与皮肤的粘合力极佳,因此可用作膏药、各种医用垫和药物浸渍皮肤病药物的粘合层。
查看更多

同类化合物

阿扑长春胺 长春醇 长春酸胺 长春西汀杂质N 长春西汀杂质L 长春西汀杂质K 长春西汀杂质J 长春西汀杂质I 长春西汀杂质27 长春西汀杂质1 长春西汀杂质 A 长春西汀 长春胺杂质 长春胺杂质 长春胺乙酯 长春胺 长春泊林 长春布宁 长春倍酯 长春乙酯羧酸 象牙酮宁 溴长春胺 富马酸溴长春胺 埃那胺 7-氨基-4-羟基-3-(苯偶氮基)萘-2-磺基酸 14,15-二氢阿扑长春胺乙酯 13alpha-乙基-2,3,5,6,13a,13b-六氢-1H-吲哚并(3,2,1-去)吡啶并(3,2,1-ij)(1,5)-萘啶-12-羧酸甲氧基甲基酯 (3alpha,16alpha)-6-羟基-象牙洪达木烯宁-14(15H)-酮 (3alpha,14beta,16alpha)-14,15-二氢-14-羟基埃那美宁-14-甲醇 (+)-(14beta)-二氢长春西丁 (+/-)-vincaminine (3α)-Eburnamenine-14-carbonyl chloride hydrochloride (-)-3S,16R-14-benzoyloxymethyl-eburnamenine apovincamine acetylsalicylate (+)-vinpocetine-9,11-disulfonic acid (3-methoxypropyl)diamide 14-(aminomethyl)-vincane O-((eburnamenine-14-yl)methyl)(4-methoxyphenyl)carbamothioate O-((eburnamenine-14-yl)methyl)(4-chlorophenyl)carbamothioate O-((eburnamenine-14-yl)methyl)(morpholine-4-carbonyl)(phenyl)carbamothioate (+)-14-carboxy-eburnamenine(3,16)-10-sulfonamide vinpocetine hydrochloride (+)-14-(2-chloro)carboethoxy-eburnamenine(3,16)-10-sulfonic acid (3-methoxypropyl)amide (+)-14-carbopropyloxy-eburnamenine(3,16)-10-sulfonic acid (3-methoxypropyl)amide (+)-apovincamine-10-sulfonic acid (3-methoxypropyl)amide 4-oxide 6-hydroxy-py-tetrahydroapovincamine chloride 10-nitro-6-oxovincamine (41S,13aS)-13a-ethyl-N,N-dimethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5] naphthyridine-12-carboxamide N-(((41S,13aS)-13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridin-12-yl)methyl)isobutyramide vincamine acetylsalicylate 6-hydroxy-py-tetrahydro-16-deoxyepivincamine chloride